New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
08:47 EDTEPZMEpizyme price target raised to $52 from $37 at Wedbush
Wedbush increased its price target on Epizyme after the company released clinical data on its EPZ-5676 treatment that the firm views as positive. The firm reiterates an Outperform rating on the stock.
News For EPZM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
08:05 EDTEPZMEpizyme presents EPZ-6438 pre-clinical data
Subscribe for More Information
October 10, 2014
08:02 EDTEPZMEpizyme announces presentation of EPZ-6438, EPZ-5676 data
Epizyme announced that clinical and pre-clinical data on its histone methyltransferase inhibitors will be highlighted in oral and poster presentations at the 56th annual meeting of the American Society of Hematology to be held December 6-9 in San Francisco, California. The company will present data from EPZ-5676 and EPZ-6438 studies.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use